Clinical Trials Directory

Trials / Completed

CompletedNCT04742374

Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Comparison of the Effects of 2 Therapeutic Plasmapheresis Techniques: Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). A Monocentric Prospective Study With a Single-Case Experimental Design

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described. Treatments include corticotherapy, IVIg and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques - single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood samplingBlood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis

Timeline

Start date
2021-03-12
Primary completion
2023-12-18
Completion
2023-12-18
First posted
2021-02-08
Last updated
2025-12-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04742374. Inclusion in this directory is not an endorsement.